EP Patent

EP2533798A2 — P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth

Assigned to Universitaet Bremen · Expires 2012-12-19 · 13y expired

What this patent protects

Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying antitumor agents are described. Furthermore, novel methods and compositions are provided for the treatme…

USPTO Abstract

Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying antitumor agents are described. Furthermore, novel methods and compositions are provided for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of obesity are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP2533798A2
Jurisdiction
EP
Classification
—
Expires
2012-12-19
Drug substance claim
No
Drug product claim
No
Assignee
Universitaet Bremen
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.